Pyxis Oncology, Inc. (PYXS)
Health Care · Oncology-focused biotechnology; antibody-drug conjugates · NASDAQ
Pyxis Oncology is a clinical-stage biopharma developing innovative antibody-drug conjugates (ADCs) that target the tumor microenvironment to improve efficacy in difficult-to-treat solid tumors.
What Pyxis Oncology, Inc. does
Pyxis Oncology is a clinical-stage biotechnology company focused on developing novel antibody-drug conjugates (ADCs) to treat patients with solid tumors. Its lead product candidate, micvotabart pelidotin (MICVO), targets the extradomain-B of fibronectin (EDB+FN) in the tumor microenvironment to deliver a potent microtubule inhibitor payload. The company is primarily investigating this candidate in patients with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
Themes: ADC / antibody-drug conjugates, Oncology / solid tumors, Head and neck cancer (HNSCC), Tumor microenvironment targeting, Immuno-oncology
Fundamentals
- Price$3.34 as of 2026-08-26 close
- Market cap$279M as of 2026-08-26
- 1-year return+143.8% 2025-08-26 close $1.37 → 2026-08-26 close $3.34
- P/En/a negative earnings
- Net margin-574.5% as of 2026-08-27
- Gross margin+82.8% as of 2026-08-27
- ROE-70.8% as of 2026-08-27
- Debt / equity0.00 as of 2026-08-27
- Revenue growth (YoY)-14.2% as of 2026-08-27
- Beta1.33 as of 2026-08-27
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How PYXS compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-27
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-27
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-27
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-27
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Pyxis Oncology, Inc. looks technically
Pyxis Oncology, Inc. (PYXS) is trading 41.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago. It is 39.8% below its highest point of the past year. Trading volume is unusually light — only about 48% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 41.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +41.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.76 | $2.76 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.36 | $2.36 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.5. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal | 14 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 41.3% above | +41.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.90 to $4.00) — its "stochastic" reading is 69 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 68.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.55 | $5.55 |
|---|---|---|
| From the 52-week high | it is 39.8% below its 52-week high (its highest price of the past year) | -39.8% |
| Above the 52-week low | it is 224.3% above its 52-week low (its lowest price of the past year) | +224.3% |
| Below the 52-week high | it is 39.8% below its highest point of the past year | 39.8% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $14.00 (set on 2021-11-03) | $14.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.06 to $5.34), and it has recovered around half of its fall from last year’s high — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.71 to $3.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 53.3% |
| From the all-time high | it is 76.1% below its all-time high | -76.1% |
| Nearest price level | it is trading 1.6% below a resistance level at $3.39 — a price it turned at twice since 2024-09-06, most recently on 2026-06-30. Since 2024-08-26 it has 9 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.6% |
| All-time low | its lowest closing price on record is $0.833 (set on 2025-04-07) | $0.833 |
| Above the all-time low | it is 301.0% above its all-time low | +301.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3625 between its high and its low — about 10.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3625 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.55 and $3.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.55 – $3.16 – $3.76 |
| Typical daily range (% of price) | its price moves about 10.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.8% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (41.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 48% of its 30-day average | 0.48× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.5% since the prior reading | -1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-26 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Gap filled | a 2.1% gap down opened on 2026-08-20 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +12.84% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 24.3 percentage points (the stock gained 28.0% while the market gained 3.7%) | +24.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 102.8 percentage points (the stock gained 104.9% while the market gained 2.1%) | +102.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 108.6 percentage points (the stock gained 119.7% while the market gained 11.1%) | +108.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 125.1 percentage points (the stock gained 143.8% while the market gained 18.7%) | +125.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 33% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.3% of the share price, which is taken to mean a barrier that gives way easily. | +32.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 45% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $2.31 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +44.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.10 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +7.6% |
Price levels it has turned at before
PYXS last closed at $3.34 on 2026-08-26. Since 2024-08-26 it has turned at 9 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.39 | Resistance | 1.6% above the last close | turned there twice · 2024-09-06 to 2026-06-30 |
| $3.89 | Resistance | 16.4% above the last close | turned there twice · 2024-09-10 to 2025-10-10 |
| $1.83 | Support | 45.2% below the last close | turned there twice · 2025-01-07 to 2026-04-14 |
| $1.70 | Support | 49.3% below the last close | turned there twice · 2026-02-06 to 2026-03-18 |
| $1.50 | Support | 55.1% below the last close | turned there twice · 2024-12-19 to 2024-12-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.50.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $0.1022 and $1.40 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.50.
This reading has stood for 1 trading day, since 2026-08-26.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Analyst price target recently CUT · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$7.22 range $5.00 – $12.00; median $7.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PYXS
- Consensus EPS estimate-$0.2778 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial doubt about ability to continue as a going concern; requires additional capital to finance operations over several years","Lead product candidate MICVO is in early-stage clinical development with uncertain outcome; failure in clinical trials or inability to obtain regulatory approval would materially harm the company","Dependence on third-party manufacturers and critical license agreements (including Pfizer license); breach of these agreements could prevent development and commercialization of MICVO"]
What changed in the latest 10-Q
AI-assisted comparison of PYXS's 10-Q filed 2026-05-14 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 'Fiscal 2025 10-K' (filed 2026-05-14) vs. older references 'Fiscal 2024 10-K' (filed 2025-11-03)
- Newer filing includes description of MICVO's three-pronged mechanism of action: (1) direct payload kill, (2) bystander effect, (3) immunogenic cell death (ICD) triggering via neoantigens
- Newer filing specifies payload as 'Aur0101' (optimized auristatin)
- Newer filing mentions MICVO being studied in combination with KEYTRUDA (pembrolizumab) in 1L/2L+ R/M HNSCC and other solid tumors
- Newer filing describes Phase 1 Part 2 dose expansion initiated in January 2025 with two specific cohorts defined (Arm 1 for platinum/PD-L1 prior therapy, Arm 2 for EGFR/PD-L1 prior therapy)
- Newer filing references December 2025 positive preliminary data from Phase 1 monotherapy study (text appears truncated)
- Removed:
- Older filing's broader description of tumor ECM as 'complex network of fibrous proteins and molecules' with discussion of embryogenesis expression of EDB+FN
- Older filing's description that MICVO can kill 'activated fibroblasts and vascular endothelial cells that support tumor growth'
- Older filing's statement that payload kills tumor cells 'through a combination of bystander effect directly killing highly proliferative cells and through stimulation of the local immune cells'
- Older filing's mention of dose response observations across nine solid tumor types with 26% ORR in six specific tumor types at therapeutic dose range
- Older filing's reference to October 2025 ESMO Congress 2025 presentation in Berlin and AACR-NCI-EORTC reference
- Reworded:
- Older: 'clinical stage oncology company executing on a development strategy designed to address' → Newer: 'clinical-stage oncology company advancing a development strategy focused on addressing'
- Older: MICVO 'formerly referred to as PYX-201' → Newer: 'formerly PYX-201'
- Older: 'Extradomain-B Fibronectin (EDB+FN)' → Newer: 'the splice variant of fibronectin, extradomain-B of fibronectin (EDB+FN)'
- Older: 'human Immunoglobulin G1 (IgG1)' → Newer: 'fully human IgG1 monoclonal antibody'
- Older: 'optimized auristatin' → Newer: 'optimized auristatin (Aur0101) microtubule inhibitor payload'
- Older: describes linker as enabling 'delivery of the next generation auristatin payload' → Newer: describes cleavable linker mechanism in detail with reference to extracellular proteases under acidic conditions
- Notes:
- Newer filing MD&A appears truncated mid-sentence at 'In December 2025, we reported positive preliminary data from our ongoing Phase 1 mon', limiting full comparison of later sections
- Older filing references 'Recent Translation Data' section beginning with October 2025 ESMO presentation, but this section is not included in the provided newer text excerpt
Risk Factors
- Added:
- Added statement in second bullet point: 'We have substantial doubt about our ability to continue as a going concern' (filed 2026-05-14)
- Added reference to product candidate name: 'micvotabart pelidotin (MICVO), formerly known as PYX-201' in third bullet point (filed 2026-05-14)
- Added phrase in sixth bullet point: 'We may face significant competition from other oncology-focused biotechnology' (emphasis on 'oncology-focused') (filed 2026-05-14)
- Removed:
- Removed notation '(MICVO), formerly known as PYX-201' was not present in older version - older version only stated 'micvotabart pelidotin' (filed 2025-11-03)
- Removed 'going concern' language entirely from older second bullet point (filed 2025-11-03)
- Removed 'oncology-focused' descriptor from competition risk in older sixth bullet point (filed 2025-11-03)
- Reworded:
- Second bullet point revised from 'We will require substantial additional capital' to 'We have substantial doubt about our ability to continue as a going concern and we will require substantial additional capital' (filed 2026-05-14)
- Second bullet point expanded to state potential consequence of capital needs includes inability to 'continue as a going concern or we may be forced' (filed 2026-05-14)
- Sixth bullet point changed from 'We face significant competition from other biotechnology' to 'We may face significant competition from other oncology-focused biotechnology' (filed 2026-05-14)
- Notes:
- Financial statements in the two filings are for different reporting periods (March 31, 2026 vs. September 30, 2025 and December 31, 2024), so direct financial comparison between periods is not the focus of this Risk Factors analysis
- The summary risk factors section text provided is truncated in both versions, ending mid-sentence; full context of all changes cannot be fully assessed
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($107100) — 1 selling insider
- Last 180 days0 buys · 1 sell ($107100) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-30. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PYXS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PYXS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,066,617
- Reported value $3,017,262
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PYXS had 4,172,154 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PYXS had 5.00% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.19 days to cover at the same settlement.
- Reported short interest (shares) 4,172,154
- Short interest (% of shares outstanding) 5.00%
- Prior settlement (shares) 3,253,653
- Reported change 28.23%
- Days to cover (reported) 4.19
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Genmab
- Daiichi Sankyo
- Seattle Genetics/Seagen
- Pfizer (oncology ADC programs)
- Celldex Therapeutics
- Mersana Therapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PYXS vs…
Pyxis Oncology, Inc. is found in…
Frequently asked questions
What does Pyxis Oncology, Inc. (PYXS) do?
Pyxis Oncology is a clinical-stage biotechnology company focused on developing novel antibody-drug conjugates (ADCs) to treat patients with solid tumors. Its lead product candidate, micvotabart pelidotin (MICVO), targets the extradomain-B of fibronectin (EDB+FN) in the tumor microenvironment to deliver a potent microtubule inhibitor payload. The company is primarily investigating this candidate in patients with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
What sector is Pyxis Oncology, Inc. (PYXS) in?
Pyxis Oncology, Inc. (PYXS) is classified in the Health Care sector. Its industry is Oncology-focused biotechnology; antibody-drug conjugates. It trades on NASDAQ.
Who are Pyxis Oncology, Inc.'s (PYXS) competitors?
Notable peers of Pyxis Oncology, Inc. (PYXS) include Genmab, Daiichi Sankyo, Seattle Genetics/Seagen, Pfizer (oncology ADC programs) and Celldex Therapeutics. This peer set is informational only — not financial advice.
Is Pyxis Oncology, Inc. (PYXS) overbought or oversold right now?
Pyxis Oncology, Inc. (PYXS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PYXS come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.